Annexon Inc (NASDAQ: ANNX) — Healthcare · Share Price, Chart & Market Data
About: Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $6.30 (+0.56%)
ANNXAnnexon Inc
Loading watchlist status…
Trade ANNX now
Annexon Inc share price
ANNX price activity
Last Price
Change (24hr)
USD (%)
Volume
Volume (4w avg)
Previous Close
N/A
Last Trade
Delayed
23 Apr, 2:17 pm GMT+0
ANNX price performance
-0.553%
5D
17.225%
1M
34.222%
YTD
242.12%
1Y
ANNX price fundamentals
N/A
Shares Issued
N/A
Dividends Per Share (DPS)
N/A
Earnings Per Share (EPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
NASDAQ rank
N/A
Sector Rank
N/A
Delayed
23 Apr, 2:17 pm GMT+0
ANNX details
ANNX Market Signals